Physician profile
Bimal Patel
NPI 1871729566
$2,731.50
in general payments reported to CMS, 2019-2025
23 companies · $452 in 2025
The $452 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2020: $184 · 2021: $512 · 2022: $671 · 2023: $347 · 2024: $293 · 2025: $452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,093.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,092.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $624.95 | 2019-2025 | |
| Pfizer INC. | $315.09 | 2019-2025 | |
| Biotronik INC. | $248.69 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $190.58 | 2022-2025 | Eliquis, Camzyos |
| Abbott Laboratories | $186.35 | 2019-2022 | |
| Boston Scientific Corporation | $151.14 | 2019-2024 | Sq-Rx Pulse Generator |
| Angiodynamics, INC. | $133.56 | 2022 | |
| Vertos Medical, INC. | $127.01 | 2021-2022 | |
| Tactile Systems Technology INC | $114.65 | 2023-2025 | Flexitouch Plus, Entre Plus, Nimbl |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.71 | 2022-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $105.44 | 2019-2022 | |
| Amgen INC. | $86.80 | 2023-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals Lp | $52.10 | 2024-2025 | Farxiga, Lokelma |
| Novo Nordisk INC | $46.20 | 2024 | Wegovy, Rybelsus, Ozempic |
| Regeneron Healthcare Solutions, INC. | $42.15 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $30.19 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $27.90 | 2024 | Lifevest |
| Alnylam Pharmaceuticals INC. | $26.97 | 2025 | Amvuttra |
| Depuy Synthes Sales INC. | $26.15 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $23.42 | 2023 | Inpefa |
| Medtronic, INC. | $21.91 | 2021 | |
| Abbvie INC. | $20.73 | 2025 | |
| Janssen Biotech, INC. | $19.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bimal Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.